Lucentis ranibizumab: Preliminary Phase IIIb data

Preliminary data from the double-blind Phase IIIb PIER trial in 184 patients showed that Lucentis met the primary endpoint. At month 12, patients treated with 0.3 and 0.5 mg Lucentis lost 1.6 and 0.2 ...